Climb Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Climb Bio, Inc. (Nasdaq: CLYM) on June 11, 2026. The filing discloses initial clinical data from the Phase 1b portion of a Phase 1b/2a study (NCT07043946) evaluating budoprutug, an anti-CD19 monoclonal antibody, for the treatment of primary immune thrombocytopenia (ITP) in adults.
Key Clinical Metrics and Financial Status
Clinical Data (as of June 1, 2026):
- Enrollment: 15 patients enrolled across 250 mg (n=6) and 500 mg (n=9) dose cohorts.
- Follow-up: Median follow-up of 38 weeks (250 mg) and 12 weeks (500 mg).
- Population: Heavily pretreated patients with a median of 6 to 7.5 prior lines of therapy.
- Safety: Budoprutug was well tolerated; no serious adverse events, no treatment discontinuations due to adverse events, and no infusion-related reactions. All adverse events were Grade 1 to Grade 2.
- Efficacy (250 mg cohort): B-cell depletion averaged over 90% by Week 4. Mean platelet count increased by 111,000 platelets/µL at Week 24.
- Response Durability: 4 of 6 patients achieved durable platelet responses; 2 of 6 maintained platelet levels ≥100 x 10³/µL for over 24 weeks.
- Rituximab-Refractory Patients: Of 4 patients previously treated with rituximab, 3 responded, with 2 achieving durable and complete responses.
Financial Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Outlook
The primary material event is the positive initial clinical data supporting the continued evaluation of budoprutug in ITP. Enrollment in the 1000 mg dose cohort is ongoing. The Company expects to announce additional data from the study by year-end 2026.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks identified include:
- Timely and successful integration of the Tenet Medicines, Inc. acquisition and technology transfer from Beijing Mabworks Biotech Co., Ltd.
- Ability to advance budoprutug and CLYM116 on expected timelines and obtain regulatory approvals.
- Replicating early-stage positive results in larger clinical trials.
- Competition in the treatment of immune-mediated diseases.
- Intellectual property protection and management of expenses.
- The need to raise substantial additional capital to continue development.
Investor Verification Checklist
- Verify the full safety profile and adverse event details in the upcoming year-end 2026 data release.
- Confirm the timeline and criteria for advancing to the Phase 2a portion of the study.
- Assess the Company's current cash runway and capital raising plans given the stated need for substantial additional funding.
- Review the status of the Tenet Medicines acquisition integration and the Beijing Mabworks license agreement.
- Monitor enrollment progress in the 1000 mg dose cohort.